Jan 5, 2011

The FDA’s second-in-command Joshua Sharfstein is stepping down as principal deputy commissioner to become Maryland’s secretary of health and mental hygiene, according to The Washington Post.

Sharfstein’s resignation comes less than two years after the Obama Administration appointed him to lead its FDA transition team. Under the direction of Sharfstein and FDA Commissioner Margaret Hamburg, the agency reviewed its drug and medical device review processes and increased enforcement efforts in order to distance itself from Bush-era accusations of overly accommodating relationships with the industries it oversees, according to the Post.

Sharfstein's successor at the FDA has yet to be named.

Author

  • Stewart Eisenhart

Related

AdvaMed-sponsored Study: FDA Less Efficient than EU Regulators

A new study sponsored by the US medical device industry trade association Advanced Medical Technology Association (AdvaMed), “EU Medical Device Approval Safety Assessment,” has found that the European regulatory system has performed just as effectively in terms of public safety as the US Food and Drug Administration while simultaneously providing a speedier and more efficient path to market for manufacturers.

Read more

August 23rd Deadline for FDA Final Rule on Three Obsolete Class III Devices

A final FDA rule affecting ventricular bypass devices, pacemaker repair or replacement material

Read more

Comment Period Extended for FDA’s Guidance on 510(k) Device Modifications

The US Food and Drug Administration has extended its comment period to November 28, 2011 for guidance the agency issued

Read more

Have questions on what Emergo can do for you?

CONTACT US